Podcast & CME Activities

CLICK ON STATES TO SEE LIVE ACTIVITIES

Podcast

Topic: Supporting the Mental Health of Frontline Healthcare Workers
 
Jul
30
Thu
Supporting the Mental Health of Frontline Healthcare Workers
Jul 30 2020 @ 8:30 am – Jul 30 2021 @ 8:45 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Mental Health: Supporting Frontline Healthcare Workers

VIEW ACTIVITY

Aug
14
Fri
Social Issues in Management of COVID-19
Aug 14 2020 @ 12:00 am – Aug 14 2021 @ 12:00 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Social Issues: Identifying Social Barriers in the Management of COVID-19

VIEW ACTIVITY

Aug
31
Mon
Treatment Options: Evaluating Evidence for Emerging Agents
Aug 31 2020 @ 6:16 am – Aug 31 2021 @ 7:16 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Treatment Options: Evaluating Evidence for Emerging Agents

VIEW ACTIVITY

Sep
25
Fri
ICU Management: Managing Critically Ill Patients with COVID-19
Sep 25 2020 @ 3:36 pm – Sep 25 2021 @ 4:36 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: ICU Management: Managing Critically Ill Patients with COVID-19

VIEW ACTIVITY

Nov
13
Fri
Emerging Vaccines Against SARS-CoV-2
Nov 13 2020 @ 3:36 pm – Nov 13 2021 @ 11:59 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Vaccines: Preventing the Spread of COVID-19

VIEW ACTIVITY

Online Programs

Nov
20
Fri
COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19
Nov 20 2020 @ 9:00 am – Nov 20 2021 @ 11:59 pm

 

COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19

VIEW ACTIVITY

 

Dec
23
Wed
COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Dec 23 2020 @ 12:00 am – Dec 23 2021 @ 11:45 pm

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

VIEW ACTIVITY

 

 

FACULTY

Michael Niederman MD, MACP, FCCP, FCCM, FERS
Associate Division Chief
Clinical Director, Pulmonary and Critical Care
New York Presbyterian/ Weill Cornell Medical Center
Professor of Clinical Medicine
Weill Cornell Medical College
New York, NY

PROGRAM OVERVIEW

This program will explore the use of agents recently granted emergency use authorization for the management of COVID-19. Clinicians will learn about the mechanism of action of monoclonal antibodies against COVID-19, how to identify patients who are at risk for developing severe COVID-19, and discuss best practices on incorporating these agents into clinical practice to prevent the development of severe COVID-19 in recently diagnosed patients. This activity will also explore the use of baricitinib in combination with remdesivir for patients hospitalized with COVID-19 and provide guidance on how to select patients who would benefit from this therapy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of a variety of specialties, including infectious disease specialists, pulmonary medicine specialists, emergency room practitioners, advanced practitioners, nurses, and other healthcare professionals to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of dual neutralizing monoclonal antibody cocktail therapies recently granted emergency use authorizations (EUAs) for patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 0.75 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits: 0.75 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Niederman has conducted research for Bayer, Merck, and Shionogi and is a consultant for Pfizer, Merck, Bayer, Thermo-Fisher, Nabriva, and N8 Medical.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this live virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based live activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: December 23, 2020

EXPIRATION DATE: December 23, 2021

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

ONLINE ACTIVITIES

Nov
20
Fri
COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19
Nov 20 2020 @ 9:00 am – Nov 20 2021 @ 11:59 pm

 

COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19

VIEW ACTIVITY

 

Dec
23
Wed
COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Dec 23 2020 @ 12:00 am – Dec 23 2021 @ 11:45 pm

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

VIEW ACTIVITY

 

 

FACULTY

Michael Niederman MD, MACP, FCCP, FCCM, FERS
Associate Division Chief
Clinical Director, Pulmonary and Critical Care
New York Presbyterian/ Weill Cornell Medical Center
Professor of Clinical Medicine
Weill Cornell Medical College
New York, NY

PROGRAM OVERVIEW

This program will explore the use of agents recently granted emergency use authorization for the management of COVID-19. Clinicians will learn about the mechanism of action of monoclonal antibodies against COVID-19, how to identify patients who are at risk for developing severe COVID-19, and discuss best practices on incorporating these agents into clinical practice to prevent the development of severe COVID-19 in recently diagnosed patients. This activity will also explore the use of baricitinib in combination with remdesivir for patients hospitalized with COVID-19 and provide guidance on how to select patients who would benefit from this therapy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of a variety of specialties, including infectious disease specialists, pulmonary medicine specialists, emergency room practitioners, advanced practitioners, nurses, and other healthcare professionals to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of dual neutralizing monoclonal antibody cocktail therapies recently granted emergency use authorizations (EUAs) for patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 0.75 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits: 0.75 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Niederman has conducted research for Bayer, Merck, and Shionogi and is a consultant for Pfizer, Merck, Bayer, Thermo-Fisher, Nabriva, and N8 Medical.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this live virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based live activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: December 23, 2020

EXPIRATION DATE: December 23, 2021

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

BOOTH TOUR

Jul
30
Thu
Supporting the Mental Health of Frontline Healthcare Workers
Jul 30 2020 @ 8:30 am – Jul 30 2021 @ 8:45 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Mental Health: Supporting Frontline Healthcare Workers

VIEW ACTIVITY

Aug
14
Fri
Social Issues in Management of COVID-19
Aug 14 2020 @ 12:00 am – Aug 14 2021 @ 12:00 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Social Issues: Identifying Social Barriers in the Management of COVID-19

VIEW ACTIVITY

Aug
31
Mon
Treatment Options: Evaluating Evidence for Emerging Agents
Aug 31 2020 @ 6:16 am – Aug 31 2021 @ 7:16 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Treatment Options: Evaluating Evidence for Emerging Agents

VIEW ACTIVITY

Sep
25
Fri
ICU Management: Managing Critically Ill Patients with COVID-19
Sep 25 2020 @ 3:36 pm – Sep 25 2021 @ 4:36 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: ICU Management: Managing Critically Ill Patients with COVID-19

VIEW ACTIVITY

Nov
13
Fri
Emerging Vaccines Against SARS-CoV-2
Nov 13 2020 @ 3:36 pm – Nov 13 2021 @ 11:59 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Vaccines: Preventing the Spread of COVID-19

VIEW ACTIVITY

Nov
20
Fri
COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19
Nov 20 2020 @ 9:00 am – Nov 20 2021 @ 11:59 pm

 

COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19

VIEW ACTIVITY

 

Dec
23
Wed
COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Dec 23 2020 @ 12:00 am – Dec 23 2021 @ 11:45 pm

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

VIEW ACTIVITY

 

 

FACULTY

Michael Niederman MD, MACP, FCCP, FCCM, FERS
Associate Division Chief
Clinical Director, Pulmonary and Critical Care
New York Presbyterian/ Weill Cornell Medical Center
Professor of Clinical Medicine
Weill Cornell Medical College
New York, NY

PROGRAM OVERVIEW

This program will explore the use of agents recently granted emergency use authorization for the management of COVID-19. Clinicians will learn about the mechanism of action of monoclonal antibodies against COVID-19, how to identify patients who are at risk for developing severe COVID-19, and discuss best practices on incorporating these agents into clinical practice to prevent the development of severe COVID-19 in recently diagnosed patients. This activity will also explore the use of baricitinib in combination with remdesivir for patients hospitalized with COVID-19 and provide guidance on how to select patients who would benefit from this therapy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of a variety of specialties, including infectious disease specialists, pulmonary medicine specialists, emergency room practitioners, advanced practitioners, nurses, and other healthcare professionals to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of dual neutralizing monoclonal antibody cocktail therapies recently granted emergency use authorizations (EUAs) for patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 0.75 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits: 0.75 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Niederman has conducted research for Bayer, Merck, and Shionogi and is a consultant for Pfizer, Merck, Bayer, Thermo-Fisher, Nabriva, and N8 Medical.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this live virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based live activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: December 23, 2020

EXPIRATION DATE: December 23, 2021

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

GRAND ROUNDS

Jul
30
Thu
Supporting the Mental Health of Frontline Healthcare Workers
Jul 30 2020 @ 8:30 am – Jul 30 2021 @ 8:45 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Mental Health: Supporting Frontline Healthcare Workers

VIEW ACTIVITY

Aug
14
Fri
Social Issues in Management of COVID-19
Aug 14 2020 @ 12:00 am – Aug 14 2021 @ 12:00 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Social Issues: Identifying Social Barriers in the Management of COVID-19

VIEW ACTIVITY

Aug
31
Mon
Treatment Options: Evaluating Evidence for Emerging Agents
Aug 31 2020 @ 6:16 am – Aug 31 2021 @ 7:16 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Treatment Options: Evaluating Evidence for Emerging Agents

VIEW ACTIVITY

Sep
25
Fri
ICU Management: Managing Critically Ill Patients with COVID-19
Sep 25 2020 @ 3:36 pm – Sep 25 2021 @ 4:36 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: ICU Management: Managing Critically Ill Patients with COVID-19

VIEW ACTIVITY

Nov
13
Fri
Emerging Vaccines Against SARS-CoV-2
Nov 13 2020 @ 3:36 pm – Nov 13 2021 @ 11:59 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Vaccines: Preventing the Spread of COVID-19

VIEW ACTIVITY

Nov
20
Fri
COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19
Nov 20 2020 @ 9:00 am – Nov 20 2021 @ 11:59 pm

 

COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19

VIEW ACTIVITY

 

Dec
23
Wed
COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Dec 23 2020 @ 12:00 am – Dec 23 2021 @ 11:45 pm

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

VIEW ACTIVITY

 

 

FACULTY

Michael Niederman MD, MACP, FCCP, FCCM, FERS
Associate Division Chief
Clinical Director, Pulmonary and Critical Care
New York Presbyterian/ Weill Cornell Medical Center
Professor of Clinical Medicine
Weill Cornell Medical College
New York, NY

PROGRAM OVERVIEW

This program will explore the use of agents recently granted emergency use authorization for the management of COVID-19. Clinicians will learn about the mechanism of action of monoclonal antibodies against COVID-19, how to identify patients who are at risk for developing severe COVID-19, and discuss best practices on incorporating these agents into clinical practice to prevent the development of severe COVID-19 in recently diagnosed patients. This activity will also explore the use of baricitinib in combination with remdesivir for patients hospitalized with COVID-19 and provide guidance on how to select patients who would benefit from this therapy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of a variety of specialties, including infectious disease specialists, pulmonary medicine specialists, emergency room practitioners, advanced practitioners, nurses, and other healthcare professionals to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of dual neutralizing monoclonal antibody cocktail therapies recently granted emergency use authorizations (EUAs) for patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 0.75 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits: 0.75 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Niederman has conducted research for Bayer, Merck, and Shionogi and is a consultant for Pfizer, Merck, Bayer, Thermo-Fisher, Nabriva, and N8 Medical.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this live virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based live activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: December 23, 2020

EXPIRATION DATE: December 23, 2021

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

Jul
30
Thu
Supporting the Mental Health of Frontline Healthcare Workers
Jul 30 2020 @ 8:30 am – Jul 30 2021 @ 8:45 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Mental Health: Supporting Frontline Healthcare Workers

VIEW ACTIVITY

Aug
14
Fri
Social Issues in Management of COVID-19
Aug 14 2020 @ 12:00 am – Aug 14 2021 @ 12:00 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Social Issues: Identifying Social Barriers in the Management of COVID-19

VIEW ACTIVITY

Aug
31
Mon
Treatment Options: Evaluating Evidence for Emerging Agents
Aug 31 2020 @ 6:16 am – Aug 31 2021 @ 7:16 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Treatment Options: Evaluating Evidence for Emerging Agents

VIEW ACTIVITY

Sep
25
Fri
ICU Management: Managing Critically Ill Patients with COVID-19
Sep 25 2020 @ 3:36 pm – Sep 25 2021 @ 4:36 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: ICU Management: Managing Critically Ill Patients with COVID-19

VIEW ACTIVITY

Nov
13
Fri
Emerging Vaccines Against SARS-CoV-2
Nov 13 2020 @ 3:36 pm – Nov 13 2021 @ 11:59 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Vaccines: Preventing the Spread of COVID-19

VIEW ACTIVITY

Nov
20
Fri
COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19
Nov 20 2020 @ 9:00 am – Nov 20 2021 @ 11:59 pm

 

COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19

VIEW ACTIVITY

 

Dec
23
Wed
COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Dec 23 2020 @ 12:00 am – Dec 23 2021 @ 11:45 pm

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

VIEW ACTIVITY

 

 

FACULTY

Michael Niederman MD, MACP, FCCP, FCCM, FERS
Associate Division Chief
Clinical Director, Pulmonary and Critical Care
New York Presbyterian/ Weill Cornell Medical Center
Professor of Clinical Medicine
Weill Cornell Medical College
New York, NY

PROGRAM OVERVIEW

This program will explore the use of agents recently granted emergency use authorization for the management of COVID-19. Clinicians will learn about the mechanism of action of monoclonal antibodies against COVID-19, how to identify patients who are at risk for developing severe COVID-19, and discuss best practices on incorporating these agents into clinical practice to prevent the development of severe COVID-19 in recently diagnosed patients. This activity will also explore the use of baricitinib in combination with remdesivir for patients hospitalized with COVID-19 and provide guidance on how to select patients who would benefit from this therapy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of a variety of specialties, including infectious disease specialists, pulmonary medicine specialists, emergency room practitioners, advanced practitioners, nurses, and other healthcare professionals to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of dual neutralizing monoclonal antibody cocktail therapies recently granted emergency use authorizations (EUAs) for patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 0.75 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits: 0.75 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Niederman has conducted research for Bayer, Merck, and Shionogi and is a consultant for Pfizer, Merck, Bayer, Thermo-Fisher, Nabriva, and N8 Medical.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this live virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based live activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: December 23, 2020

EXPIRATION DATE: December 23, 2021

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

A Virtual Reality Learning Experience: Integrating GLP-1 Receptor Agonists into T2DM Practice—Why, When, and How

Jul
30
Thu
Supporting the Mental Health of Frontline Healthcare Workers
Jul 30 2020 @ 8:30 am – Jul 30 2021 @ 8:45 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Mental Health: Supporting Frontline Healthcare Workers

VIEW ACTIVITY

Aug
14
Fri
Social Issues in Management of COVID-19
Aug 14 2020 @ 12:00 am – Aug 14 2021 @ 12:00 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Social Issues: Identifying Social Barriers in the Management of COVID-19

VIEW ACTIVITY

Aug
31
Mon
Treatment Options: Evaluating Evidence for Emerging Agents
Aug 31 2020 @ 6:16 am – Aug 31 2021 @ 7:16 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Treatment Options: Evaluating Evidence for Emerging Agents

VIEW ACTIVITY

Sep
25
Fri
ICU Management: Managing Critically Ill Patients with COVID-19
Sep 25 2020 @ 3:36 pm – Sep 25 2021 @ 4:36 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: ICU Management: Managing Critically Ill Patients with COVID-19

VIEW ACTIVITY

Nov
13
Fri
Emerging Vaccines Against SARS-CoV-2
Nov 13 2020 @ 3:36 pm – Nov 13 2021 @ 11:59 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Vaccines: Preventing the Spread of COVID-19

VIEW ACTIVITY

Nov
20
Fri
COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19
Nov 20 2020 @ 9:00 am – Nov 20 2021 @ 11:59 pm

 

COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19

VIEW ACTIVITY

 

Dec
23
Wed
COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Dec 23 2020 @ 12:00 am – Dec 23 2021 @ 11:45 pm

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

VIEW ACTIVITY

 

 

FACULTY

Michael Niederman MD, MACP, FCCP, FCCM, FERS
Associate Division Chief
Clinical Director, Pulmonary and Critical Care
New York Presbyterian/ Weill Cornell Medical Center
Professor of Clinical Medicine
Weill Cornell Medical College
New York, NY

PROGRAM OVERVIEW

This program will explore the use of agents recently granted emergency use authorization for the management of COVID-19. Clinicians will learn about the mechanism of action of monoclonal antibodies against COVID-19, how to identify patients who are at risk for developing severe COVID-19, and discuss best practices on incorporating these agents into clinical practice to prevent the development of severe COVID-19 in recently diagnosed patients. This activity will also explore the use of baricitinib in combination with remdesivir for patients hospitalized with COVID-19 and provide guidance on how to select patients who would benefit from this therapy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of a variety of specialties, including infectious disease specialists, pulmonary medicine specialists, emergency room practitioners, advanced practitioners, nurses, and other healthcare professionals to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of dual neutralizing monoclonal antibody cocktail therapies recently granted emergency use authorizations (EUAs) for patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 0.75 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits: 0.75 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Niederman has conducted research for Bayer, Merck, and Shionogi and is a consultant for Pfizer, Merck, Bayer, Thermo-Fisher, Nabriva, and N8 Medical.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this live virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based live activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: December 23, 2020

EXPIRATION DATE: December 23, 2021

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

Jul
30
Thu
Supporting the Mental Health of Frontline Healthcare Workers
Jul 30 2020 @ 8:30 am – Jul 30 2021 @ 8:45 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Mental Health: Supporting Frontline Healthcare Workers

VIEW ACTIVITY

Aug
14
Fri
Social Issues in Management of COVID-19
Aug 14 2020 @ 12:00 am – Aug 14 2021 @ 12:00 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Social Issues: Identifying Social Barriers in the Management of COVID-19

VIEW ACTIVITY

Aug
31
Mon
Treatment Options: Evaluating Evidence for Emerging Agents
Aug 31 2020 @ 6:16 am – Aug 31 2021 @ 7:16 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Treatment Options: Evaluating Evidence for Emerging Agents

VIEW ACTIVITY

Sep
25
Fri
ICU Management: Managing Critically Ill Patients with COVID-19
Sep 25 2020 @ 3:36 pm – Sep 25 2021 @ 4:36 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: ICU Management: Managing Critically Ill Patients with COVID-19

VIEW ACTIVITY

Nov
13
Fri
Emerging Vaccines Against SARS-CoV-2
Nov 13 2020 @ 3:36 pm – Nov 13 2021 @ 11:59 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Vaccines: Preventing the Spread of COVID-19

VIEW ACTIVITY

Nov
20
Fri
COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19
Nov 20 2020 @ 9:00 am – Nov 20 2021 @ 11:59 pm

 

COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19

VIEW ACTIVITY

 

Dec
23
Wed
COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Dec 23 2020 @ 12:00 am – Dec 23 2021 @ 11:45 pm

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

VIEW ACTIVITY

 

 

FACULTY

Michael Niederman MD, MACP, FCCP, FCCM, FERS
Associate Division Chief
Clinical Director, Pulmonary and Critical Care
New York Presbyterian/ Weill Cornell Medical Center
Professor of Clinical Medicine
Weill Cornell Medical College
New York, NY

PROGRAM OVERVIEW

This program will explore the use of agents recently granted emergency use authorization for the management of COVID-19. Clinicians will learn about the mechanism of action of monoclonal antibodies against COVID-19, how to identify patients who are at risk for developing severe COVID-19, and discuss best practices on incorporating these agents into clinical practice to prevent the development of severe COVID-19 in recently diagnosed patients. This activity will also explore the use of baricitinib in combination with remdesivir for patients hospitalized with COVID-19 and provide guidance on how to select patients who would benefit from this therapy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of a variety of specialties, including infectious disease specialists, pulmonary medicine specialists, emergency room practitioners, advanced practitioners, nurses, and other healthcare professionals to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of dual neutralizing monoclonal antibody cocktail therapies recently granted emergency use authorizations (EUAs) for patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 0.75 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits: 0.75 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Niederman has conducted research for Bayer, Merck, and Shionogi and is a consultant for Pfizer, Merck, Bayer, Thermo-Fisher, Nabriva, and N8 Medical.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this live virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based live activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: December 23, 2020

EXPIRATION DATE: December 23, 2021

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Copyright © 2020 | COVID Frontline | All Rights Reserved | Website by Divigner

Patient Toolkit

The COVID FRONTLINE Patient Toolkit is a resource center for patients who have been diagnosed with or who are interested in learning about COVID-19. Choose from the options below to learn more.

Clinical Toolkit

The COVID-19 Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for COVID-19. Click on one of the options below to learn more.

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Merck & Co., Inc., and Pfizer.

Copyright © 2019 | COVID Frontline | All Rights Reserved | Website by Divigner

Updates in the Treatment and Prevention of COVID-19​

Emergency use authorization for casirivimab/imdevimab in patients with mild-to-moderate COVID-19

The combination of the monoclonal antibodies casirivimab and imdevimab (previously known as REGN-COV2) has been authorized for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (≥12 years of age and ≥40 kg) who are at high risk for progressing to severe COVID-19 or hospitalization.1

Interim results from 275 nonhospitalized patients in a placebo-controlled trial of casirivimab plus imdevimab found that the combination therapy reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Patients who received casirivimab/imdevimab required fewer medical visits for COVID-19 than patients who received placebo (3% vs 6%, respectively). Among patients who were serum antibody-negative at baseline, 15% in the placebo group and 6% in the treatment group required COVID-19-related medical care.2 

Baricitinib in combination with remdesivir authorized for emergency use in hospitalized patients

Baricitinib, in combination with remdesivir, is authorized for emergency use in adult and pediatric patients ≥2 years of age hospitalized for COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).3

A recent trial of 1033 patients hospitalized for COVID-19 found that baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time (7 days vs 8 days, respectively; P= .03). Patients receiving high-flow oxygen or noninvasive ventilation at enrollment had a time to recovery of 10 days with combination therapy and 18 days with the control (rate ratio for recovery, 1.51). The addition of baricitinib to remdesivir was associated with 30% higher odds of improvement in clinical status at day 15 compared with remdesivir alone.4 

 

References 

  1. Emergency use authorization (EUA) of casirivimab and imdevimab. Available at fda.gov/media/143892/download Accessed 12/23/2020.
  2. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2020;Dec 17:Epub ahead of print. Available at nejm.org/doi/full/10.1056/NEJMoa2035002Accessed 12/23/2020.
  3. Emergency use authorization (EUA) of baricitinib. Available at fda.gov/media/143823/download Accessed 12/23/2020.
  4. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020;Dec 11:Epub ahead of print. Available at nejm.org/doi/full/10.1056/NEJMoa2031994 Accessed 12/23/2020.